News
RNXT
1.220
-3.94%
-0.050
Weekly Report: what happened at RNXT last week (0422-0426)?
Weekly Report · 5d ago
RenovoRx files to sell 6.96M shares of common stock for holders
RenovoRx files to sell 6.96M shares of common stock for holders. The company filed a prospectus related to the resale by the selling stockholders of 6.95 million shares of stock. This prospectus is not an offer to sell the stock.
Seeking Alpha · 04/26 21:18
Weekly Report: what happened at RNXT last week (0415-0419)?
Weekly Report · 04/22 11:13
RENOVORX REGAINS COMPLIANCE WITH NASDAQ STOCKHOLDERS’ EQUITY REQUIREMENT
Reuters · 04/18 12:30
RENOVORX INC <RNXT.O>: ALLIANCE GLOBAL PARTNERS CUTS TARGET PRICE TO $3.5 FROM $4
Reuters · 04/15 14:34
RenovoRx Secures $11.1M Through Equity and Warrants Offering
TipRanks · 04/15 13:12
RENOVORX CLOSES $11.1 MILLION PRIVATE PLACEMENT, PROVIDING CASH RUNWAY INTO 2026
Reuters · 04/15 12:00
Weekly Report: what happened at RNXT last week (0408-0412)?
Weekly Report · 04/15 11:04
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are worth checking out on Tuesday morning. Biophytis stock is rocketing close to 50% after announcing its 2023 results. Moving stocks this morning are earnings reports, clinical trial data and more. Biggest Pre-Market Stock Movers include 10 top gainers and 10 top losers.
Investorplace · 04/09 11:27
RNXT Stock Earnings: RenovoRx Meets EPS for Q4 2023
RenovoRx reported earnings per share of -30 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. This met the analyst estimate for EPS of -20 cents. Renovorx reported results for the last quarter of 2013.
Investorplace · 04/08 17:52
INKT, BROG and ETAO among mid-day movers
On the Move INKT, BROG and ETAO among mid-day movers. Auddia and Etao International Co Ltd. Are among the gainers. 22nd Century Group Inc. Is one of the biggest losers in the SA market on Thursday.
Seeking Alpha · 04/08 16:24
RenovoRx to raise $11.1 million in a private placement; shares rise
RenovoRx to raise $11.1 million in a private placement; shares rise 12% in pre-market trade. The company said its cash position now expected to fund current operating plan into 2026. Shares in the company up 12% before the opening bell.
Seeking Alpha · 04/08 12:45
RenovoRx Executes Definitive Subscription Agreement With Accredited Investors For $11.1M At Market Private Placement
Cash position now expected to fund current operating plan into 2026. Financing provides cash runway to advance the ongoing pivotal Phase III TIGeR-PaC trial. Also enables the expansion of RenovoRx's clinical development pipeline into additional cancer indications.
Benzinga · 04/08 12:36
RENOVORX ANNOUNCES $11.1 MILLION AT MARKET PRIVATE PLACEMENT
Reuters · 04/08 12:30
RENOVORX INC - PROCEEDS FROM FINANCING ARE ALSO EXPECTED TO ENABLE EXPANSION OF TAMP CLINICAL DEVELOPMENT PIPELINE INTO ADDITIONAL CANCER INDICATIONS
Reuters · 04/08 12:30
Weekly Report: what happened at RNXT last week (0401-0405)?
Weekly Report · 04/08 11:10
RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024
RenovoRx, Inc. Is a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform. Shaun Bagai will present at the Canaccord Genuity 2024 Horizons in Oncology Virtual Conference to be held on April 15, 2024. The company’s lead product candidate, RenovoGem, is being evaluated for the treatment of locally advanced pancreatic cancer.
Barchart · 04/05 07:30
Weekly Report: what happened at RNXT last week (0325-0329)?
Weekly Report · 04/01 11:08
Weekly Report: what happened at RNXT last week (0318-0322)?
Weekly Report · 03/25 11:10
Weekly Report: what happened at RNXT last week (0311-0315)?
Weekly Report · 03/18 11:09
More
Webull provides a variety of real-time RNXT stock news. You can receive the latest news about Renovorx Inc through multiple platforms. This information may help you make smarter investment decisions.
About RNXT
RenovoRx, Inc. is a clinical-stage biopharmaceutical company. The Company is developing targeted combination therapies for high unmet medical needs with a goal of improving therapeutic outcomes for cancer patients undergoing treatment. Its Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. Its portfolio of cancer therapies is based on its lead product candidate, RenovoGem (gemcitabine delivered via its delivery system). Its phase III lead product candidate, RenovoGem, is a novel oncology drug-device combination product. RenovoGem is being evaluated for the treatment of locally advanced pancreatic cancer (LAPC) by the Center for Drug Evaluation and Research. Its phase III registrational trial of RenovoGem for the treatment of LAPC is called TIGeR-PaC.